Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

What Is Shingles? What Causes Shingles?
Shingles is caused by the herpes varicella-zoster (or simply zoster) virus. This virus also causes chickenpox. Most of us get chickenpox during childhood, but after we recover the virus remains inactive (dormant) in our nervous system. Our immune system stops the virus from becoming active. However, later in life it may become reactivated, causing shingles. Shingles is an infection of a nerve and the area of skin around it.

New Family-Focused Model Of Depression Care Needed To Minimize Risks And Problems For Parents With Depression And Their Children
Health and social service professionals who care for adults with depression should not only tackle their clients" physical and mental health, but also detect and prevent possible spillover effects on their children, says a new report from the National Research Council and Institute of Medicine. To achieve this new family-focused model of depression care, federal and state agencies, nonprofits, and the private sector will have to experiment with nontraditional ways of organizing, paying for, and delivering services, said the committee that wrote the report.
News of the day
An 'Eye Catching' Vision Discovery
Nearly all species have some ability to detect light. At least three types of cells in the retina allow us to see images or distinguish between night and day. Now, researchers at the Johns Hopkins School of Medicine have discovered in fish yet another type of cell that can sense light and contribute to vision.
Oncology

Pharming Receives Agreement On Paediatric Investigation Plan For Rhucin(R) From The EMEA Paediatric Committee

Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that the Paediatric Committee (PDCO) of the European Medicines Agency (EMEA) has adopted an opinion agreeing the paediatric investigation plan (PIP) for Rhucin® (recombinant human C1 inhibitor) in the therapeutic area of immunology-rheumatology transplantation. "Agreement of the PIP represents a key milestone in Pharming"s regulatory plans for the September 2009 submission of the Rhucin marketing authorisation application," said Dr. Bruno Giannetti, COO of Pharming. According to the EC Regulation 1901/2006 of 12 December 2006, pharmaceutical companies that submit an application for a marketing authorisation for a medicinal product (MAA) in the EU, have to include an approved PIP as part of the regulatory submission. Pharming Group NV


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009